Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hugo M Horlings

Showing results (71-80 of 103) with videos related to

Pageof 11
Sort By:
The Journal of Pathology|May 11, 2013
Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencingIan J Majewski, Lorenza Mittempergher, Nadia M Davidson, et al.
Cancers|December 11, 2022
Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian CancerLilian van Wagensveld, Juliette O A M van Baal, Maite Timmermans, et al.
Iscience|August 29, 2024
Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trialMark Opdam, Annelot G J van Rossum, Marlous Hoogstraat, et al.
Genome Medicine|October 27, 2015
HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancerAndrew E Teschendorff, Shih-Han Lee, Allison Jones, et al.
NPJ Breast Cancer|May 22, 2020
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trialsJan Hudeček, Leonie Voorwerk, Maartje van Seijen, et al.
International Journal of Cancer|May 18, 2022
Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trialSimone N Koole, Philip C Schouten, Jan Hauke, et al.
Nature Cancer|April 10, 2023
PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trialLeonie Voorwerk, Olga I Isaeva, Hugo M Horlings, et al.
Cancer Discovery|February 9, 2026
Single-cell spatial atlas of high-grade serous ovarian cancer uncovers MHC class II as a key predictor of spatial tumor ecosystems and clinical outcomesFernando Perez-Villatoro, Aleksandra Shabanova, Lilian van Wagensveld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell MicroenvironmentsLennart Kester, Danielle Seinstra, Annelot G J van Rossum, et al.
Nature Genetics|April 25, 2017
Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypesYi Kan Wang, Ali Bashashati, Michael S Anglesio, et al.
Pageof 11

Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
The Journal of Pathology|May 11, 2013
Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencingIan J Majewski, Lorenza Mittempergher, Nadia M Davidson, et al.
Cancers|December 11, 2022
Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian CancerLilian van Wagensveld, Juliette O A M van Baal, Maite Timmermans, et al.
Iscience|August 29, 2024
Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trialMark Opdam, Annelot G J van Rossum, Marlous Hoogstraat, et al.
Genome Medicine|October 27, 2015
HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancerAndrew E Teschendorff, Shih-Han Lee, Allison Jones, et al.
NPJ Breast Cancer|May 22, 2020
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trialsJan Hudeček, Leonie Voorwerk, Maartje van Seijen, et al.
International Journal of Cancer|May 18, 2022
Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trialSimone N Koole, Philip C Schouten, Jan Hauke, et al.
Nature Cancer|April 10, 2023
PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trialLeonie Voorwerk, Olga I Isaeva, Hugo M Horlings, et al.
Cancer Discovery|February 9, 2026
Single-cell spatial atlas of high-grade serous ovarian cancer uncovers MHC class II as a key predictor of spatial tumor ecosystems and clinical outcomesFernando Perez-Villatoro, Aleksandra Shabanova, Lilian van Wagensveld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell MicroenvironmentsLennart Kester, Danielle Seinstra, Annelot G J van Rossum, et al.
Nature Genetics|April 25, 2017
Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypesYi Kan Wang, Ali Bashashati, Michael S Anglesio, et al.
Pageof 11